Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

H.C. Wainwright reiterates Buy on Teva Pharma stock, $54 target

H.C. Wainwright reiterates Buy on Teva Pharma stock, $54 target

H.C. Wainwright has reaffirmed its Buy rating on Teva Pharmaceutical Industries (NYSE:TEVA) and maintained a $54.00 price target. The firm noted that Teva's management has expressed confidence in the continuity of research and development efforts following Eric Hughes' departure as Chief Medical Officer and Executive Vice President of Global R&D.

David Gardiner, Head of Innovative Medicines & Clinical Development, is now leading the R&D transition, reporting directly to CEO Richard Francis. Hughes is expected to oversee the handover until year-end, with external R&D communications transferring to Gardiner. Teva CEO Francis expressed confidence that Hughes' departure would not affect the execution of existing programs, including duvakitug and IL-15, which are managed by dedicated program and regulatory leads.

Teva reported third-quarter revenue of $4.395 billion, a 2% year-over-year decline but a 6% sequential increase. Non-GAAP earnings per share were $0.86, beating consensus estimates of $0.72. Teva also settled a patent infringement lawsuit with Alkermes and announced positive responses to its recent R&D Day from other analyst firms.

H.C. Wainwright raised its price target to $54, highlighting Teva's shift towards an innovation-led biopharmaceutical company.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at investing.com →

More in Finance & Markets

More from Friday 20 November →